397 related articles for article (PubMed ID: 32004571)
1. Glioblastoma precision therapy: From the bench to the clinic.
Zhou Y; Wu W; Bi H; Yang D; Zhang C
Cancer Lett; 2020 Apr; 475():79-91. PubMed ID: 32004571
[TBL] [Abstract][Full Text] [Related]
2. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma targeted therapy: updated approaches from recent biological insights.
Touat M; Idbaih A; Sanson M; Ligon KL
Ann Oncol; 2017 Jul; 28(7):1457-1472. PubMed ID: 28863449
[TBL] [Abstract][Full Text] [Related]
4. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
5. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
Mao H; Lebrun DG; Yang J; Zhu VF; Li M
Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
[TBL] [Abstract][Full Text] [Related]
6. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
[TBL] [Abstract][Full Text] [Related]
7. Molecular targeting of glioblastoma: Drug discovery and therapies.
Bai RY; Staedtke V; Riggins GJ
Trends Mol Med; 2011 Jun; 17(6):301-312. PubMed ID: 21411370
[TBL] [Abstract][Full Text] [Related]
8. Novel CXCR4 Inhibitor CPZ1344 Inhibits the Proliferation, Migration and Angiogenesis of Glioblastoma.
Luo Z; Wang B; Chen Y; Liu H; Shi L
Pathol Oncol Res; 2020 Oct; 26(4):2597-2604. PubMed ID: 32632898
[TBL] [Abstract][Full Text] [Related]
9. Overview of Transforming Growth Factor β Superfamily Involvement in Glioblastoma Initiation and Progression.
Nana AW; Yang PM; Lin HY
Asian Pac J Cancer Prev; 2015; 16(16):6813-23. PubMed ID: 26514451
[TBL] [Abstract][Full Text] [Related]
10. The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment.
Chang N; Ahn SH; Kong DS; Lee HW; Nam DH
Mol Cell Endocrinol; 2017 Aug; 451():53-65. PubMed ID: 28089821
[TBL] [Abstract][Full Text] [Related]
11. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
Zhang N; Wei L; Ye M; Kang C; You H
Front Immunol; 2020; 11():592612. PubMed ID: 33329578
[TBL] [Abstract][Full Text] [Related]
12. Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery-A Comprehensive Review of the Literature.
Alomari S; Zhang I; Hernandez A; Kraft CY; Raj D; Kedda J; Tyler B
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944514
[TBL] [Abstract][Full Text] [Related]
13. Toward precision medicine in glioblastoma: the promise and the challenges.
Prados MD; Byron SA; Tran NL; Phillips JJ; Molinaro AM; Ligon KL; Wen PY; Kuhn JG; Mellinghoff IK; de Groot JF; Colman H; Cloughesy TF; Chang SM; Ryken TC; Tembe WD; Kiefer JA; Berens ME; Craig DW; Carpten JD; Trent JM
Neuro Oncol; 2015 Aug; 17(8):1051-63. PubMed ID: 25934816
[TBL] [Abstract][Full Text] [Related]
14. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma Therapy in the Age of Molecular Medicine.
Geraldo LHM; Garcia C; da Fonseca ACC; Dubois LGF; de Sampaio E Spohr TCL; Matias D; de Camargo Magalhães ES; do Amaral RF; da Rosa BG; Grimaldi I; Leser FS; Janeiro JM; Macharia L; Wanjiru C; Pereira CM; Moura-Neto V; Freitas C; Lima FRS
Trends Cancer; 2019 Jan; 5(1):46-65. PubMed ID: 30616755
[TBL] [Abstract][Full Text] [Related]
16. Potential role for STAT3 inhibitors in glioblastoma.
Jackson C; Ruzevick J; Amin AG; Lim M
Neurosurg Clin N Am; 2012 Jul; 23(3):379-89. PubMed ID: 22748651
[TBL] [Abstract][Full Text] [Related]
17. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.
El Meskini R; Iacovelli AJ; Kulaga A; Gumprecht M; Martin PL; Baran M; Householder DB; Van Dyke T; Weaver Ohler Z
Dis Model Mech; 2015 Jan; 8(1):45-56. PubMed ID: 25431423
[TBL] [Abstract][Full Text] [Related]
18. Molecular Mechanisms of Drug Resistance in Glioblastoma.
Dymova MA; Kuligina EV; Richter VA
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203727
[TBL] [Abstract][Full Text] [Related]
19. Using the molecular classification of glioblastoma to inform personalized treatment.
Olar A; Aldape KD
J Pathol; 2014 Jan; 232(2):165-77. PubMed ID: 24114756
[TBL] [Abstract][Full Text] [Related]
20. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
